Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
PURINERGIC RECEPTORS AND METABOLIC FUNCTION
Autore:
PETIT P; LOUBATIERESMARIANI MM; KEPPENS S; SHEEHAN MJ;
Indirizzi:
FAC MED MONTPELLIER,UPRES EA 1677,PHARMACOL LAB,BLVD HENRI IV F-34060MONTPELLIER 1 FRANCE KATHOLIEKE UNIV LEUVEN,AFDELING BIOCHEM B-3001 LOUVAIN BELGIUM GLAXO WELLCOME INC,MED RES CTR,RECEPTOR PHARMACOL UNIT STEVENAGE HERTS ENGLAND
Titolo Testata:
Drug development research
fascicolo: 3-4, volume: 39, anno: 1996,
pagine: 413 - 425
SICI:
0272-4391(1996)39:3-4<413:PRAMF>2.0.ZU;2-S
Fonte:
ISI
Lingua:
ENG
Soggetto:
PERFUSED RAT PANCREAS; INSULIN-SECRETING CELLS; LIVER PLASMA-MEMBRANES; GLUCAGON-SECRETION; ADENOSINE-TRIPHOSPHATE; ADENYLATE-CYCLASE; DIABETIC RAT; FATTY-ACID; HEPATOCYTES; ADIPOCYTES;
Keywords:
PURINOCEPTORS; PANCREATIC B CELL; PANCREATIC A CELL; HEPATOCYTE; ADIPOCYTE;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
67
Recensione:
Indirizzi per estratti:
Citazione:
P. Petit et al., "PURINERGIC RECEPTORS AND METABOLIC FUNCTION", Drug development research, 39(3-4), 1996, pp. 413-425

Abstract

Blood glucose concentration is a signal for the endocrine pancreas torelease insulin or glucagon. Insulin lowers the level of glucose by inhibiting the hepatic glucose production and stimulating glucose utilization by skeletal muscles and adipocytes. In these latter cells, insulin also inhibits lipolysis and the subsequent release of glycerol (a gluconeogenic precursor) and non esterified fatty acids (energy substrate for hepatic gluconeogenesis). Glucagon opposes the effects of insulin, particularly in the liver, where it stimulates glycogenolysis andneoglucogenesis. A variety of purinoceptor subtypes are expressed in these different tissues, all involved in the regulation of glucose homeostasis: 1) P2Y and A(1) receptors in the pancreatic B cell, mediating stimulation or inhibition of insulin secretion respectively, A(2) receptors in the pancreatic A cell mediating glucagon secretion; 2) different P2 receptors in liver cells mediating glycogenolysis through multiple transducing systems; 3) A(1) receptors in adipocytes mediating antilipolytic action. The thorough characterization of these receptors,together with a better understanding of their metabolic role and position in this integrated physiological regulation may be useful in designing ligands aimed at stimulating insulin secretion or reducing insulin resistance, which are both critical in the pathophysiology of non-insulin-dependent diabetes mellitus (NIDDM). Thus, purinoceptors may constitute new targets for pharmacological compounds with potential therapeutic applications in NIDDM, such as P2Y agonists as insulin secretagogues and A(1) agonists as antilipolytic agents for improvement of insulin sensitivity. (C) 1997 Wiley-Liss, Inc.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 15/07/20 alle ore 08:33:41